News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-01-04-2017
Volume12
Issue 1

AGC Asahi Glass Acquires CMC Biologics

AGC adds second biopharma contract manufacturer with acquisition of CMC Biologics.

CMC Biologics, a contract developer and manufacturer of monoclonal antibodies, coagulation factors, and other therapeutic proteins for clinical and commercial applications, announced on Dec. 19, 2016, that it has entered into an agreement with AGC Asahi Glass (AGC) in which AGC will acquire 100% of CMC Biologics’ shares. This acquisition is expected to close in January 2017. 

CMC Biologics will retain its brand and independence and does not anticipate changes in operations, the current leadership team, or employee base, as reported in a press statement announcing the deal.

Founded in Denmark in 2001, CMC Biologics now has more than 500 employees, two commercial-phase manufacturing facilities, and one early-phase manufacturing facility.

In September 2016, ACG acquired another biopharmaceutical contract manufacturer, Biomeva, based in Heidelberg, Germany.

Sources: CMC Biologics and AGC Asahi Glass

 

 

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content